Regeneron Wins FDA Nod for EYLEA HD Extended Dosing
TARRYTOWN, N.Y., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Regeneron
Advertisement
Regeneron Partners with TriNetX for 300M Patient Data
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to...
Dupixent Approved in Japan for Rare Skin Disease
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Regeneron and Tessera Unite to Develop TSRA-196 Therapy
Tarrytown, New York & Somerville, Massachusetts, December 1, 2025 — Regeneron and Tessera Therapeutics have announced a global collaboration...
EU Approves Dupixent as First Targeted CSU Therapy
TARRYTOWN, N.Y. & PARIS — November 25, 2025. The European Commission has granted landmark approval for Dupixent® (dupilumab) as...
Advertisement
